Leadership
The COPDforum leadership is comprised of renowned researchers/clinicians in COPD, who have contributed significantly
to the developments in this field. This global group represents some of the world's thought leaders in this area,
who are prominent in respiratory publications, international and local societies and research initiatives. Click on the
links below to learn more about the COPDforum leadership.
Leadership
P.N. Richard Dekhuijzen
MD, PhD, Professor of Medicine
Netherlands
Place of Work
Radboud University Nijmegen Medical Centre, the Netherlands.
Experience
Professor P.N. Richard Dekhuijzen is Professor of Pulmonology
and Head of the Department of Pulmonary Diseases, Radboud
University Nijmegen Medical Centre, the Netherlands. His specific
area of research interest is in asthma and COPD, with a focus on
pathophysiology and therapeutic interventions.
He studied Medicine at the Free University Amsterdam and
completed his training in Pulmonology at the Onze Lieve Vrouwe
Gasthuis in Amsterdam and in the Academic Hospital in Nijmegen. In
1989, he finished his PhD thesis on training of the respiratory
muscles in COPD. In 1991 to 1992, he worked as a post-doctorate
fellow at the Catholic University Leuven, Belgium, followed by a
PhD thesis on steroid-induced myopathy of the diaphragm in
1994.
He was Associate Editor of the European Respiratory Journal and
regularly reviews for the major respiratory journals. He is author
and/or co-author of over 200 peer-reviewed papers and many text
book chapters on Respiratory Medicine. He was chairman of the
Committee on the Development of Guidelines in Respiratory Medicine
of the Dutch Society of Pulmonology, and member of the Scientific
Board of the Dutch Asthma Foundation. Recently, he chaired the
Dutch guidelines on the treatment of COPD. In addition, he was
appointed as Chairman of the Heart-Lung Centre in Nijmegen, the
Netherlands.
Recent publications
van Ingen J, Lindeboom JA, Hartwig NG, de Zwaan R, Tortoli E,
Dekhuijzen PNR, Boeree MJ, van Soolingen D.
Mycobacterium mantenii sp. nov., a pathogenic, slowly growing,
scotochromogenic mycobacterium. Int J Syst Evol Microbiol. 2009 Jul
22. [Epub ahead of print]
van Ingen J, Boeree MJ, Kösters K, Wieland A, Tortoli E,
Dekhuijzen PNR, van Soolingen D. Proposal to
elevate Mycobacterium avium complex ITS sequevar MAC-Q to
Mycobacterium vulneris sp. nov. Int J Syst Evol Microbiol. 2009 Jul
20. [Epub ahead of print]
van Ingen J, de Zwaan R, Dekhuijzen PNR, Boeree
M, van Soolingen D. The Region of Difference 1 in nontuberculous
Mycobacterium species adds a phylogenetic and taxonomical
character. J Bacteriol. 2009 Jul 17. [Epub ahead of print]
Broeders ME, Sanchis J, Levy ML, Crompton GK, Dekhuijzen
PNR; ADMIT Working Group. The ADMIT series--issues in
inhalation therapy. 2. Improving technique and clinical
effectiveness. Prim Care Respir J. 2009 Jun;18(2):76-82.
Review.
van Ingen J, Al-Hajoj SA, Boeree M, Al-Rabiah F, Enaimi M, de
Zwaan R, Tortoli E, Dekhuijzen PNR, van Soolingen
D. Mycobacterium riyadhense sp. nov., a non-tuberculous species
identified as Mycobacterium tuberculosis complex by a commercial
line-probe assay. Int J Syst Evol Microbiol. 2009 May;59(Pt
5):1049-53.
Schuurbiers OC, Kaanders JH, van der Heijden HF,
Dekhuijzen PNR, Oyen WJ, Bussink J. The
PI3-K/AKT-pathway and radiation resistance mechanisms in non-small
cell lung cancer. J Thorac Oncol. 2009 Jun;4(6):761-7. Review.
Koenders MM, Wismans RG, Starcher B, Hamel BC,
Dekhuijzen PNR, van Kuppevelt TH. Fibrillin-1
staining anomalies are associated with increased staining for
TGF-beta and elastic fibre degradation; new clues to the
pathogenesis of emphysema. J Pathol. 2009 Aug;218(4):446-57.
van Ingen J, van der Laan T, Amaral L, Dekhuijzen
PNR, Boeree MJ, van Soolingen D. In vitro activity of
thioridazine against mycobacteria. Int J Antimicrob Agents. 2009
Aug;34(2):190-1. Epub 2009 Apr 5. No abstract available.
Al-Mahruqi SH, van-Ingen J, Al-Busaidy S, Boeree MJ, Al-Zadjali
S, Patel A, Richard-Dekhuijzen PNR, van-Soolingen
D. Clinical relevance of nontuberculous Mycobacteria, Oman. Emerg
Infect Dis. 2009 Feb;15(2):292-4.
Schermer T, Chavannes N, Dekhuijzen PNR,
Wouters E, Muris J, Akkermans R, van Schayck O, van Weel C.
Fluticasone and N-acetylcysteine in primary care patients with COPD
or chronic bronchitis. Respir Med. 2009 Apr;103(4):542-51. Epub
2009 Jan 9.
Heunks LM, Dekhuijzen PNR. Mechanical
ventilation and disuse atrophy of the diaphragm. N Engl J Med. 2008
Jul 3;359(1):90; author reply 91-2. No abstract available.
van Ingen J, Boeree MJ, de Lange WC, Hoefsloot W, Bendien SA,
Magis-Escurra C, Dekhuijzen PNR, van Soolingen D.
Mycobacterium xenopi clinical relevance and determinants, the
Netherlands. Emerg Infect Dis. 2008 Mar;14(3):385-9.
Stege G, Vos PJ, van den Elshout FJ, Dekhuijzen
PNR, van de Ven MJ, Heijdra YF. Sleep, hypnotics and
chronic obstructive pulmonary disease. Respir Med. 2008
Jun;102(6):801-14. Epub 2008 Mar 7. Review.
Ottenheijm CA, Heunks LM, Dekhuijzen PNR.
Diaphragm adaptations in patients with COPD. Respir Res. 2008 Jan
24;9:12.
Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders
M, Dekhuijzen PNR, Sanchis J, Viejo JL, Barnes P,
Corrigan C, Levy M, Crompton GK. Effect of incorrect use of dry
powder inhalers on management of patients with asthma and COPD.
Respir Med. 2008 Apr;102(4):593-604. Epub 2007 Dec 20. Review.